top of page

Clinical Trials

Dr. Martin is the principal investigator for multiple clinical trials that are investigating new devices, drugs, and treatment combinations

Untitled design.png

Pivotal Study in HCC:

Radioembolization Oncology trial Utilizing Transarterial Eye90 (ROUTE 90) for the treatment of Hepatocellular Carcinoma (HCC)

​

Indication:

Eye90 microspheres® is intended for use as internal radiation brachytherapy for local  tumor control in patients with unresectable Hepatocellular Carcinoma (HCC).  

​

Eligible Patients:

  • Confirmed diagnosis of HCC, LIRADS 5 or biopsy

  • One lesion ≥ 2 cm in diameter, no more than 3 lesions

  • Max 3 lesions and single lesion size ≤ 8 cm & sum tumor dimensions of ≤ 12 cm

  • Evidence that > 33% of the total liver volume is disease-free

  • No extra hepatic disease • Child Pugh Class A, ECOG 0-1, BCLC A, B, C

Investigator Initiated Study in HCC:
A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of IP-001 as Adjuvant Therapy in Participants with Hepatocellular Carcinoma after Complete Radiological Response following Surgical Resection and Local Ablation or Local Ablation Alone

The Study:
IP-001 is an investigational drug used as an intratumoral injection used after ablation that increases the body’s immune response after ablation

Primary Objective:
Evaluate recurrence-free survival (RFS) after curative standard of care ablation or surgical resection with and without IP-001

Key Eligibility

  • Intermediate, High, Very High Risk for Recurrence of HCC

  • Treatment plan with curative ablation or curative surgical resection & ablation

  • No extrahepatic disease

  • ECOG: 0-1

Investigator Initiated Study in Advanced Pancreatic Adenocarcinoma:

Immunotherapy and Irreversible Electroporation in the Treatment of

Locally Advanced Pancreatic Adenocarcinoma


The Study:
Immunotherapy and irreversible electroporation in the treatment of advanced pancreatic adenocarcinoma. This is a Phase II study in which all patients undergoing irreversible electroporation of locally advanced pancreatic adenocarcinoma will be treated with nivolumab post-operatively.

Primary Objective:
Evaluate efficacy, safety and tolerability of a combined treatment approach to locally advanced pancreatic cancer, utilizing both a local (IRE) and systemic Immuno-therapy.

Key Eligibility

  • Diagnosed with Stage III Pancreatic Cancer

  • Tumor Is measurable

  • Patient is a candidate irreversible electroporation

bottom of page